Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Atezolizumab + Tiragolumab
Indication/Tumor Type lung non-small cell carcinoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive lung non-small cell carcinoma predicted - sensitive Atezolizumab + Tiragolumab Phase II Actionable In a Phase II trial (CITYSCAPE), Tiragolumab (MTIG7192A) and Tecentriq (atezolizumab) combination therapy as first-line treatment improved objective response rate (37.3%, 25/67 vs 20.6%, 14/68) and median progression-free survival (5.6 vs 3.9 mo) compared to Tecentriq (atezolizumab) plus placebo in patients with CD274 (PD-L1)-positive (TPS>=1%) advanced or metastatic non-small cell lung cancer (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 9503-9503; NCT03563716). detail...
CD274 positive lung non-small cell carcinoma predicted - sensitive Atezolizumab + Tiragolumab Phase I Actionable In a Phase Ia/Ib trial (GO30103), treatment with the combination of Tecentriq (atezolizumab) and Tiragolumab (MTIG7192A) demonstrated safety and efficacy in patients with CD274 (PD-L1)-positive (>/=1%) immunotherapy-naive metastatic non-small cell lung cancer, resulting in an objective response rate of 46% (6/13, 2 complete and 4 partial responses), a disease control rate of 77% (10/13), and a duration of response of 24.2 months (PMID: 37768658; NCT02794571). 37768658
PubMed Id Reference Title Details
Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). Full reference...
(37768658) Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial. Full reference...